¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"membrane inhibitor of reactive lysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® arachnoid membrane ÇÑ±Û °Å¹Ì¸·
¼³¸í   
  ³ú¸·À» ÀÌ·ç´Â ¸·ÀÇ Çϳª. ³ú¸·À̶õ ³ú¸¦ ½Î°í Àִ ¸·À¸·Î Å©°Ô 3°³ÀÇ ¸·À¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. °¡Àå¹Ù±ù¿¡ Àִ ¸·À» °æÁú¸·(dura mater)À̶ó°í ÇÑ´Ù. ±× ´ÙÀ½ÀÇ ¸·ÀÌ °Å¹Ì¸·ÀÌ´Ù. ±×¸®°í ³ú¿¡ °­ÇϰԠ¹ÐÂøµÇ¾î Àִ °¡Àå ¾ÈÂÊÀÇ ¸·ÀÌ ¿¬¸·(pia mater)ÀÌ´Ù. °Å¹Ì¸·Àº ¿¬¸·°ú °Å¹ÌÁÙ°°Àº ±¸Á¶¹°·Î ¾ÆÁÖ ´À½¼ÇϰԠºÎÂøµÇ¾î ÀÖ´Ù. ±×·¡¼­ °Å¹Ì¸· ¹Ø¿¡´Â °ø°£ÀÌ ÀÖ´Ù. ÀÌ °ø°£À» °Å¹Ì¸·¹Ø°ø°­À̶ó°í Çϰí ÀÌ °ø°£Àº ¸¼Àº ¾×ü·Î Â÷ ÀÖ´Ù. ÀÌ ¾×ü¸¦ ³úô¼ö¾×(cerebrospinal fluid)À̶ó°í ÇÑ´Ù.
  
  °Å¹Ì¸·
  
  
¿µ¹® basement membrane ÇÑ±Û ¹Ù´Ú¸·, ±âÀú¸·
¼³¸í   
  »óÇǼ¼Æ÷, ±ÙÀ°¼¼Æ÷, ½Å°æÁ¶Á÷°ú ±×°ÍµéÀÇ ¹Ù±ùÂÊ °áÇÕÁ¶Á÷ÀÇ °æ°è¿¡ Àִ Á¡¾×´Ù´çÁú°ú ´Ü¹éÁú·Î ±¸¼ºµÈ ¾ãÀº ¸·. ±âÃʸ· ¶Ç´Â °æ°è¸·À̶ó°íµµ ÇÑ´Ù. µÎ²²´Â 50~80nmÀÌ´Ù. ±âÀú¸·Àº 20~30nm °£°ÝÀ¸·Î ´Ã¾î¼± Á·¼¼Æ÷·Î µÈ »óÇǼ¼Æ÷ÀÇ 3ÃþÀ¸·Î µÇ¾î ÀÖ°í, ºÐÀÚ·® 40,000~60,000ÀÇ ¹°ÁúÀ» Åõ°úÇÒ ¼ö ÀÖ°Ô ÇÑ´Ù. ¶ÇÇѠǥÇǿ͠ÁøÇÇÀÇ °æ°è·Î ¿µ¾çÀ» °ø±ÞÇϴ ±âÁö ¿ªÇÒÀ» ÇÑ´Ù. ÁַΠ¼¶À¯¸¦ Æ÷ÇÔÇÏ¿© ´Ù´ç·ù·Î µÇ¾î Àִµ¥, ÇöÀúÇϰԠ¹ß´ÞµÇ¾î Àִ ºÎºÐ°ú ±×·¸Áö ¾ÊÀº ºÎºÐÀÌ ÀÖ´Ù. ºñÁ¡¸·¿¡¼­´Â Á¡¸·»óÇÇÀÇ ¹Ø¿¡ ¹ß´ÞÇÑ ±âÀú¸·ÀÌ ÀÖ´Ù. ÀÌ ¸· À§¿¡ Ã»°¢¼ö¿ë¼¼Æ÷ÀΠÅм¼Æ÷¸¦ °®´Â ÄÚ¸£Æ¼±â°üÀÌ Á¸ÀçÇÑ´Ù. ±âÀú¸·Àº ÀüÁ¦°¡ À½Àü±â ¼ºÁúÀ» °¡Áö°í À־çÀü±â¸¦ °¡Áø ¹°ÁúÀÌ Åõ°úÇϱ⠽±´Ù. ±âÀú¸·ÀÌ ÆØÈ­Çϰųª ¹Ðµµ°¡ ³·¾ÆÁö¸é ´Ü¹éÁúÀÌ Åë°úÇÏ¿© ´Ü¹é´¢¸¦ ÀÏÀ¸Å°°í, ±âÀú¸·¿¡ ±Õ¿­-ÆÄ±« µîÀÌ ÀϾ¸é ÀûÇ÷±¸ µîÀÇ Ç÷¾× °íÇü¼ººÐÀÌ Åõ°úÇÏ¿© Ç÷´¢°¡ µÈ´Ù.
¿µ¹® hyaline membrane disease ÇÑ±Û À¯¸®Áú¸·º´
¼³¸í   
  ÇãÆÄ ¼º¼÷µµÀÇ ¹Ì¼÷À¸·Î ÇãÆÄ²Ê¸®¸¦ ÆØÃ¢½Ã۴ ¹°Áú(Ç¥¸éȰ¼ºÁ¦)ÀÌ ºÎÁ·ÇÏ¿© È£Èí°ï¶õÀÌ ÃÊ·¡µÇ´Â º´À¸·Î¼­ ¹Ì¼÷¾Æ¿¡ È£¹ßÇϴµ¥, Ãâ»ý½Ã ÀӽűⰣº¸´Ùµµ ÇãÆÄ ¼º¼÷ Á¤µµ°¡ ´õ °ü¿©µÈ´Ù. ´ÜÀÏ º´À¸·Î¼­´Â »ç¸Á·üÀÌ °¡Àå ³ôÀ¸¸ç(¾à 30%), ½Å»ý¾ÆÀÇ ´ëÇ¥ÀûÀΠº´ÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ¹Ì¼÷¾Æ, »ýÈÄ 6~8½Ã°£³» È£Èí°ï¶õÁõ¼¼ ÃâÇö°ú »ýÈÄ 24~48½Ã°£ÀÇ Áõ»ó ¾ÇÈ­, »ýÈÄ 2~3Àϰ£ ÀΰøÀûÀ¸·Î »ê¼Ò¸¦ °ø±ÞÇÏÁö ¾ÊÀ¸¸é È£ÈíÀ» °è¼Ó½Ãų ¼ö°¡ ¾øÀ¸¸ç Á¡Á¡´õ »ê¼ÒÀÇ °ø±Þ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö¸ç, µ¿¸ÆÇ÷¾×¼ÓÀÇ »ê¼Ò³óµµ°¡ ³»·Á°¡°í ÀÌ»êȭź¼ÒÀÇ ³óµµ°¡ ³ôÀ¸¸ç, ÈäºÎ ¹æ»ç¼± ¼Ò°ßÀ» ÂüÀÛÇÏ¿© Áø´ÜÇÑ´Ù. È¯¾Æ´Â ¼÷·ÃµÈ °£È£ Àη°ú Ã·´Ü ÀÇ·á Àåºñ°¡ ¼³Ä¡µÈ ½Å»ý¾Æ ÁýÁß Ä¡·á½Ç¿¡¼­ Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¿¹ÈĴ Áõ¼¼ÀÇ °æÁß¿¡ µû¶ó ´Ù¸£°í »ç¸Á·üÀº 30~50% µÈ´Ù. ¾î¶² ¾Æ±â¿¡ À־´Â Ä¡·á ÈÄ¿¡ ´«À̳ª ±â°üÁöÇãÆÄ °èÅë¿¡ Àå¾Ö¸¦ ÀÏÀ¸Å°´Â »ê¼ÒÁßµ¶ÁõÀÌ º¸°íµÇ°í ÀÖ´Ù.
¿µ¹® plasma membrane ÇÑ±Û ÇüÁú¸·
¼³¸í   
  ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº¸·. µÎ²²´Â 5~25¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ¿øÇüÁú¸·ÀÇ ºÐÀÚ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀǠǥ¸é È°¼º¹°Áú ºÐÀÚ°¡ 2ºÐÀÚÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿­µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼­ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï-¸í-¾ÏÀÇ 3Ãþ(°¢ ¾à 20nm)À¸·Î ±¸º°µÈ´Ù. ¿øÇüÁúÀÇ Åõ°ú¼º¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϸç, »ý¸®»óŰ¡ º¯Çϸ頱נÅõ°ú¼ºµµ ½Å¼ÓÈ÷ º¯ÇÑ´Ù. ¶Ç, ¼Õ»óÀÌ µÇ¸é ½±°Ô »õ·Î Çü¼ºµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • confluent lysis
    ¿ÏÀü¿ë±Õ
  • hot cold lysis
    ¿Â·©¿ëÇØ
  • lysis
    1. ¿ëÇØ 2. ºÐÇØ
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • C-reactive protein
    C-¹ÝÀÀ´Ü¹éÁú
  • reactive angioendotheliomatosis
    ¹ÝÀÀÇ÷°ü³»ÇÇÁ¾Áõ
  • reactive arthritis
    ¹ÝÀÀ°üÀý¿°
  • reactive attachment disorder
    ¹ÝÀÀ¼º¾ÖÂøÀå¾Ö
  • reactive bone excrescence
    ¹ÝÀÀ»Àµ¹Ãâ
  • reactive depression
    ¹ÝÀÀ¿ì¿ïÁõ
  • reactive fibrosis
    ¹ÝÀÀ¼¶À¯È­
  • reactive hyperemia
    ¹ÝÀÀÃæÇ÷
  • reactive hypoglycemia
    ¹ÝÀÀÀúÇ÷´ç(Áõ)
  • reactive inflammation
    ¹ÝÀÀ¿°Áõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lysis
    ¿ëÇØ
  • inhibitor
    ¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • thin basement membrane disease
    ¾ãÀº¹Ù´Ú¸·º´, ¾ãÀº±âÀú¸·º´
  • membrane
    ¸·
  • amnionic membrane
    ¾ç¸·
  • arachnoid membrane
    °Å¹Ì¸·
  • basement membrane
    ¹Ù´Ú¸·, ±âÀú¸·
  • mucous membrane
    Á¡¸·
  • nuclear membrane
    ÇÙ¸·
  • periorbital membrane
    (¢¡ periorbita) ´«È®»À¸·, ¾È¿Í°ñ¸·
  • plasma membrane
    ÇüÁú¸·
  • semipermeable membrane
    ¹ÝÅõ¸·
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • confluent lysis
    ¿ÏÀü¿ë±Õ
  • hot cold lysis
    ¿Â·©¿ëÇ÷
  • lysis
    ¿ëÇØ
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • reactive angioendotheliomatosis
    ¹ÝÀÀÇ÷°ü³»ÇÇÁ¾Áõ
  • reactive arthritis
    ¹ÝÀÀ°üÀý¿°
  • reactive perforating collagenosis
    ¹ÝÀÀ°üÅë¾Æ±³ÁúÁõ
  • reactive depression
    ¹ÝÀÀ¿ì¿ïÁõ
  • reactive attachment disorder
    ¹ÝÀÀ¾ÖÂøÀå¾Ö, ¹ÝÀÀ¾ÖÂøº´
  • reactive bone excrescence
    ¹ÝÀÀ»Àµ¹Ãâ
  • reactive fibrosis
    ¹ÝÀÀ¼¶À¯Áõ
  • reactive hyperemia
    ¹ÝÀÀÃæÇ÷
  • reactive hypoglycemia
    ¹ÝÀÀÀúÇ÷´çÁõ
  • reactive nodular hyperplasia
    ¹ÝÀÀ°áÀýÁõ½Ä
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Lysis
    ¿ëÇØ(éÁú°)
  • acidified-serum lysis test=Ham test
    »ê¼ºÈ­Ç÷û¿ëÇ÷°Ë»ç
  • hot cold lysis
    ¿Â·©¿ëÇ÷(è®ÕÒéÁúì)
  • rapid lysis
    ½Å¼Ó¿ë±Õ(ãöáÜéÁж).
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • CAI=£¾carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à, ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú.
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • RIMA, see reversible inhibitor of MAO-A
    °¡¿ªÀû ´Ü°¡¾Æ¹Î-A »êÈ­È¿¼Ò¾ïÁ¦Á¦
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acidified-serum lysis test=Ham test
    »ê¼ºÈ­Ç÷û¿ëÇ÷°Ë»ç
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • complement mediated lysis
    º¸Ã¼Áß°³¼º ¿ëÇØ.
  • complement mediated lysis
    º¸Ã¼¸Å°³ ¿ëÇØ.
  • confluent lysis
    À¶ÇÕ¼º ¿ë±Õ
  • euglobin clot lysis time
    À¯±Û·ÎºÒ¸°ÀÀ±«¿ëÇØ½Ã°£, À¯±Û·ÎºóÀÀ±«À¶Çؽð£
  • hot cold lysis
    ¿Â·©¿ëÇ÷(è®ÕÒéÁúì)
  • leptospira agglutination-lysis test
    ·¾Å佺ÇǶó±Õ ÀÀÁý-¿ëÇØ°Ë»ç
  • lysis
    ¿ëÇØ
  • lysis from within
    ÆÄÁö¼º ³»Àοë±Õ
  • lysis from without
    ÆÄÁö¼º ¿ÜÀοë±Õ
  • lysis inhibition
    ¿ëÇØ¾ïÁ¦(éÁú°åäð¤).
  • lysis inhibition
    ¿ëÇØÀúÇØ.
  • lysis, confluent
    ¿ÏÀü¿ë±Õ
  • lysis, osmotic
    »ïÅõ¾Ð¼º ¿ëÇØ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Vestibular wall [Vestibular membrane Reissner`s membrane]
    ¾È¶ã°è´Üº® [¾È¶ã¸·]
    [¿¾ ¿ë¾î] ÀüÁ¤º®[¸·]
  • Oropharyngeal membrane [Buccopharyngeal membrane]
    ÀÔÀεθ·
    [¿¾ ¿ë¾î] ±¸°­Àεθ·
  • (Pupillary membrane)
    (µ¿°ø¸·)
    [¿¾ ¿ë¾î] µ¿°ø¸·
  • Pleuroperitoneal membrane
    °¡½¿¸·º¹¸·¸·
    [¿¾ ¿ë¾î] È丷½É¸·¸·
  • Pleuropericardial membrane
    °¡½¿¸·½ÉÀ帷¸·
    [¿¾ ¿ë¾î] È丷½É¸·¸·
  • Suprapleural membrane
    °¡½¿¸·À§¸·
    [¿¾ ¿ë¾î] È丷»ó¸·
  • Syndesmochorial membrane
    °áÇÕÁ¶Á÷À¶¸ð¸·
    [¿¾ ¿ë¾î] °áÇÕÁ¶Á÷À¶¸ð¸·¼ºÇ÷°£°³À縷
  • Limiting membrane
    °æ°è¸·
    [¿¾ ¿ë¾î] °æ°è¸·
  • Tympanic membrane
    °í¸·
    [¿¾ ¿ë¾î] °í¸·
  • Tympanic membrane
    °í¸· [±Íû]
    [¿¾ ¿ë¾î] °í¸·
  • Tympanic membrane
    °í¸· [±Íû]
    [¿¾ ¿ë¾î] °í¸·º®
  • Branches to tympanic membrane
    °í¸·°¡Áö
    [¿¾ ¿ë¾î] °í¸·Áö
  • Umbo of tympanic membrane
    °í¸·¹è²Å
    [¿¾ ¿ë¾î] °í¸·Á¦
  • Recesses of tympanic membrane
    °í¸·¿À¸ñ
    [¿¾ ¿ë¾î] °í¸·ÇÔ¿ä
  • Tympanic wall [Spiral membrane]
    °í½Ç°è´Üº® [³ª¼±¸·]
    [¿¾ ¿ë¾î] °í½Çº®
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • egg membrane
    ³­¸·
  • embryonic membrane
    ÀÚÃæ¸·
  • outer embryophore membrane
    Á¶Ãæ¶õ¿Ü¸·
  • undulating membrane
    ÆÄµ¿¸·
  • vitelline membrane
    ³­È²¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reactive lysis
    ¹ÝÀÀ¼º ¿ëÇØ(ÚãëëàõéÁú°)
  • C-reactive protein
    C¹ÝÀÀ(Úãëë) ´Ü¹éÁú(Ó±ÛÜòõ)
  • reactive enzyme centrifugetion
    ¹ÝÀÀÈ¿¼Ò ¿ø½ÉºÐ¸®(Úãëëý£áÈêÀãýÝÂ×î)
  • reactive hemolysis
    ¹ÝÀÀ¼º ¿ëÇ÷(ÚãëëàõéÁúì)
  • reactive residue
    ¹ÝÀÀ¼º Àܱâ(ÚãëëàõíÑÐñ)
  • confluent lysis
    Àü¸é¿ëÇØ(îïØüéÁú°)
  • immune lysis
    ¸é¿ª ¿ëÇØ(Øóæ¹éÁú°)
  • lysis
    ¿ëÇØ(éÁú°)
  • lysis inhibition
    ¿ëÇØÀúÇØ(éÁú°îÁúª)
  • rapid lysis mutant
    ±Þ¿ëÇØ º¯ÀÌü(ÐáéÁú°Ü¨ì¶ô÷)
  • red cell lysis
    ÀûÇ÷±¸ ¿ëÇØ(îåúìϹéÁú°)
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • Bowman-Birk inhibitor
    "º¸¿ì¸¸-¹÷Å© ÀúÇØÀÚ(îÁúªí­), º¸¿ì¸¸-¹÷Å© ÀúÇØÁ¦(îÁúªð¥)"
  • competitive inhibitor
    °æÇÕÀúÇØÁ¦(ÌæùêîÁúªð¥)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦Á¦, ¾ïÁ¦¹°Áú, ¾ïÁ¦ÀÎÀÚ, ¾ïÁ¦½Å°æ, ¾ïÁ¦À¯ÀüÀÚ, ¾ïÁ¦¾à
  • lysis
    ¿ëÇØ, À¶ÇØ
  • C-reactive protein
    C-¹ÝÀÀ¼º´Ü¹éÁú
  • reactive bone excrescence
    ¹ÝÀÀ¼º°ñµ¹Ãâ
  • reactive fibrosis
    ¹ÝÀÀ¼º¼¶À¯È­
  • reactive hyperemia
    ¹ÝÀÀ¼ºÃæÇ÷
  • reactive interface
    ¹ÝÀÀ¼ºÁ¢Ã˸é
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • membrane
    ¸·
  • mucous membrane
    Á¡¸·
  • periorbital membrane
    ¾È¿Í°ñ¸·
  • serous membrane
    À帷
  • synovial membrane
    À±È°¸·, Ȱ¸·
  • tympanic membrane
    °í¸·
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BPTI basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in...
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
CLI complement lysis inhibitor; corpus luteum insufficiency
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
ESI elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MIRL membrane inhibitor of reactive lysis
ATLS Acute tumor lysis syndrome
ECLT Euglobulin Clot Lysis time
ELT Euglobulin Lysis Time
TLS Tumor Lysis Syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • euglobulin lysis test
    À¯±Û·ÎºÒ¸° ¿ëÇØ ½ÃÇè
  • hot cold lysis
    ¿Â³Ã ¿ëÇ÷
    ¾î¶² ¹°ÁúÀ» º¸ÅëÀ¸·Î °¡¿Â ¹ÝÀÀ½ÃŲ ÈÄ ½Ç¿Â¿¡ ¹æÄ¡Çϱ⸸ ÇÏ¿´À» ¶§ ÀϾ´Â ¿ëÇØ.
  • mazo-lysis
    ÅÂ¹Ý ¹Ú¸®
  • osmotic lysis
    »ïÅõ¼º ¿ëÇ÷
  • sucrose lysis test
    ÀÚ´ç ¿ëÇØ ½ÃÇè
  • tumor lysis syndrome
    Á¾¾ç ¿ëÇØ ÁõÈıº
    ¸Å¿ì ºü¸£°Ô ¼ºÀåÇÏ´Â ¾Ç¼º Á¾¾çÀÇ È¿°úÀûÀÎ È­ÇÐ ¿ä¹ý À¯µµ ÈÄ¿¡ ½ÉÇÑ °úÀλê Ç÷Áõ, °úÄ®·ý Ç÷Áõ, °ú¿ä»ê Ç÷Áõ, ÀúÄ®½· Ç÷ÁõÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î ¼¼Æ÷ ¿ëÇØ·Î ÀÎÇÏ¿© ¼¼Æ÷³» »ê¹°ÀÌ À¯ÃâµÇ¾î ³ªÅ¸³­´Ù°í »ý°¢µÈ´Ù.
  • whole blood clot lysis time
    ÀüÇ÷ Ç÷º´ À¶ÇØ ½Ã°£
  • acquired reactive perforating dermatosis
    ÈÄõ¼º ¹ÝÀÀ¼º õ°ø¼º ÇǺκ´
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • percent reactive antibody test
    ÆÛ¼¾Æ® ¹ÝÀÀ Ç×ü °Ë»ç
  • reactive bone excrescence
    ¹ÝÀÀ¼º °ñ µ¹Ãâ
  • reactive disease
    ¹ÝÀÀ¼º Áúȯ
  • reactive hyperemia
    ¹ÝÀÀ¼º ÃæÇ÷
    Ç÷·ù¸¦ ÀϽÃÀûÀ¸·Î Á¤Áö½ÃŲ Ç÷·ù Â÷´ÜÀ» ÇØÁ¦ÇÑ ÈÄ¿¡ ºÎºÐÀûÀ¸·Î Ç÷¾×ÀÌ °úÀ×À¸·Î µÇ´Â °Í.
  • reactive lesion
    ¹ÝÀÀ¼º º´¼Ò
  • reactive schizophrenia
    ¹ÝÀÀ¼º ºÐ¿­º´
    ¾ç¼ºÀÇ ¿¹Èİ¡ ±â´ëµÇ´Â, ÁַΠȯ°æ Á¶°Ç¿¡ ±âÀÎµÈ Á¤½Å ºÐ¿­.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
tumour lysis syndrome <haematology, oncology, syndrome> A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders.
It is characterised by combinations of hyperuricaemia, lactic acidosis, hyperkalaemia, hyperphosphatemia and hypocalcaemia.
(12 Dec 1998)
euglobulin clot lysis time A measure of the ability of plasminogen activators and plasmin to lyse a clot; normally, clot lysis is determined by the balance of factors which activate fibrinolysis (plasminogen activators and plasmin) and those which inhibit lysis; in certain conditions (e.g., carcinoma or hepatic insufficiency) activating factors predominate and can be measured by noting the time it takes the euglobulin fraction of plasma (excluding inhibitors of fibrinolysis) to clot.
(05 Mar 2000)
lysis <cell biology> Rupture of cell membranes and loss of cytoplasm.
(18 Nov 1997)
arthritis, reactive An abacterial form of arthritis developing after infection at a site distant from the affected joint or joints. The causative bacteria cannot be cultured from synovial specimens but bacterial antigens have been demonstrated in cells from the synovial fluid and membrane. It often follows yersinia infection.
(12 Dec 1998)
brief reactive psychosis <psychiatry> A brief display of psychotic behaviour that lasts for at least several hours, but not more than one week. Typically these reactions are brought on by periods of increased stress (for example death of a loved one).
Symptoms include delusions, hallucinations, disordered thinking, impaired speech and bizarre dress.
(27 Sep 1997)
reactive arthritis Reiter's syndrome is also called reactive arthritis since it is thought to involve the immune system which is reacting to the presence of bacterial infections in the genital, urinary, or gastrointestinal systems. Accordingly, certain people's immune systems are genetically primed to react aberrantly when these areas are exposed to certain bacteria. The aberrant reaction of the immune system leads to inflammation in the joints and eyes.
(12 Dec 1998)
reactive astrocyte <cell biology> A round to oval astrocyte cell with abundant cytoplasm containing glial filaments and an eccentric nucleus; may contain two nuclei in the cell hypertrophy of astrocytes.
Synonym: gemistocyte, gemistocytic cell, reactive astrocyte, reactive cell.
(05 Mar 2000)
reactive attachment disorder Markedly disturbed and developmentally inappropriate social relatedness that begins before age 5 and is associated with grossly pathological child care. The child may persistently fail to initiate and respond to social interactions in a developmentally appropriate way (inhibited type) or there may be a pattern of diffuse attachments with nondiscriminate sociability (disinhibited type).
(12 Dec 1998)
reactive cell <cell biology> A round to oval astrocyte cell with abundant cytoplasm containing glial filaments and an eccentric nucleus; may contain two nuclei in the cell hypertrophy of astrocytes.
Synonym: gemistocyte, gemistocytic cell, reactive astrocyte, reactive cell.
(05 Mar 2000)
reactive depression A psychological state occasioned directly by an intensely sad external situation (frequently loss of a loved person), relieved by the removal of the external situation (e.g., reunion with a loved person).
(05 Mar 2000)
reactive hyperaemia Hyperaemia following the arrest and subsequent restoration of the blood supply to a part.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reactive oxygen species Reactive intermediate oxygen species including both radicals and non-radicals. These substances are constantly formed in the human body and have been shown to kill bacteria and inactivate proteins, and have been implicated in a number of diseases. Scientific data exist that link the reactive oxygen species produced by inflammatory phagocytes to cancer development.
(12 Dec 1998)
reactive perforating collagenosis A rare skin disorder characterised by extrusion of collagen fibres through the epidermis; usually begins in infancy or childhood and appears clinically as recurrent umbilicated papules that resolve spontaneously. The condition may be inherited or acquired, the latter differing from Kyrle's disease because follicular involvement is absent.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦ÀÚ(¹°);¹ÝÀÀ¾ïÁ¦Á¦
  • reactive
    (Àڱؿ¡ ´ëÇØ)¹Î°¨ÇÑ;¹ÝÀÀÀÌ ºü¸¥;¹Ýµ¿(º¹°í)ÀûÀÎ;¹Ý¹ßÀûÀÎ;¹ÝÀÀÀûÀÎ;¹ÝÀÛ¿ëÀûÀÎ;~ly
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • lysis
    ¼¼Æ÷ÀÇ ¿ëÇØ;º´¼¼ °¨Åð;ȯ»ê;¼Ò»ê
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • membrane
    ¾ãÀº ¸·;¸·ÇÇ;¾çÇÇÁö;¹®¼­ÀÇ ÇÑÀå
  • mucous membrane
    Á¡¸·
  • nictitating membrane
    ¼ø¸·;(»õ ¾Ç¾îµîÀÇ ´«²¨Ç® ¾ÈÂÊ¿¡ ÀÖ´Â Á¦ 3ÀÇ ´«²¨Ç®)
  • nuclear membrane
    (»ý)ÇÙ¸·
  • tympanic membrane
    °í¸·
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á